Predicting reality

A new machine learning tool from GNS Healthcare Inc. that predicts the real-world effectiveness of new drug candidates could help companies design better postmarket studies and serve as a jumping-off point to help shape risk-sharing arrangements with payers.

Real-world evidence is now the cost of doing business, as payers frequently use the absence of it as a reason to deny preferred formulary status in competitive markets. Some companies with newly launched drugs that lack such evidence have started to use performance-based reimbursement arrangements to gain preferred access in markets like diabetes, hypercholesterolemia and heart failure. ...